RCE recce pharmaceuticals ltd

Ann: Positive Data from RECCE 327 Antibiotic Safety Studies, page-5

  1. 37,911 Posts.
    lightbulb Created with Sketch. 828
    A single 24-hour intravenous infusion administration of RECCE® 327 up to 12,000 mg/kg over the course of 7-days was carried out. Results of up 12,000 mg/kg/day was well tolerated from Days 1 to 4 (inclusive); with no mortalities or clinical signs. Day 5 onwards, there were indications of anticipated toxicity commencement. Some minor indications of a dosing limit were observed in some animals beyond the 7-day continuous intravenous infusion administration at 4,000 mg/kg (80x indicated efficacious dose).

    As per rat 7-day repeat data, it can be concluded that there was an indication of dose limit at very high levels. A single 24-hour intravenous infusion administration of RECCE® 327 up to 4000 mg/kg and 7-day continuous intravenous infusion administration of RECCE® 327 up to 500 mg/kg/day were well tolerated; with no mortalities, clinical signs, changes in body weight, coagulation, clinical chemistry or salient macroscopic abnormalities.
    Last edited by ddzx: 10/02/20
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
36.3¢
Change
0.003(0.69%)
Mkt cap ! $104.8M
Open High Low Value Volume
36.5¢ 39.5¢ 36.0¢ $72.04K 191.3K

Buyers (Bids)

No. Vol. Price($)
2 46885 36.0¢
 

Sellers (Offers)

Price($) Vol. No.
37.5¢ 1245 1
View Market Depth
Last trade - 15.58pm 23/07/2025 (20 minute delay) ?
RCE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.